RecruitingEUCTR 2017-003074-14
Samyr injections compared with placebo for depression
About this title
A study to evaluate Samyr effectiveness and safety profile. The study is done by comparing that Samyr injection is better than placebo injection in subjects with depression which are treated regularly with antidepressant tablet treatment. Uno studio per valutare l'efficacia e il profilo di sicurezza di Samyr. Lo studio viene effettuato confrontando che l'iniezione di Samyr ¿ migliore dell'iniezione di placebo in soggetti con depressione trattati regolarmente con il trattamento con compresse antidepressive.
Read the official source — EUCTR 2017-003074-14This historical record does not confirm current site availability.
Historical research recordItaly
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Giulianova and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 468
- Sponsor
- MYLAN INC.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Italy
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2017-003074-14
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr¿ IM versus Placebo IM as an Enhancer Adjunctive to Ant...
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Giulianova · Padova · Pisa
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is MYLAN INC.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® Tablet versus Placebo Tablet on top of Adjunctive Ant...
Esketamine with usual care for depression and suicidal thoughts in teens